Evertec (NYSE:EVTC) reported quarterly earnings of $0.65 per share which met the analyst consensus estimate. This is a 16.67 percent decrease over earnings of $0.78 per share from the same period last year. The company reported quarterly sales of $160.57 million which beat the analyst consensus estimate of $151.79 million by 5.78 percent. This is a 7.66 percent increase over sales of $149.15 million the same period last year.
Adial Pharmaceuticals Receives Notice Of Allowance On U.S. Patent For Treatment For Opioid Use Disorder Using AD04
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of
